Sleep Disorder That Doubles Parkinson’s Risk

A passenger sleeping on an airplane with headphones and an eye mask

Untreated sleep apnea nearly doubles your risk of developing Parkinson’s disease, but catching it early and starting treatment within two years can dramatically reduce that danger.

Quick Take

Obstructive sleep apnea affects an estimated 30 million American adults, with up to 80 percent remaining undiagnosed
People with untreated sleep apnea are nearly twice as likely to develop Parkinson’s disease compared to those who receive treatment
CPAP therapy started within two years of diagnosis can significantly lower Parkinson’s risk, reducing cases by 2.3 per 1,000 people
Sleep apnea reduces brain oxygen levels over time, potentially triggering toxic protein buildup linked to neurodegeneration
Forty percent of people already living with Parkinson’s disease experience obstructive sleep apnea, creating a vicious cycle of worsening symptoms

The Hidden Connection Between Breathing and Brain Health

For decades, sleep apnea was dismissed as a snoring problem—an annoyance rather than a genuine health threat. Recent research shatters that misconception. A landmark study analyzing millions of electronic health records reveals that untreated obstructive sleep apnea raises the risk of Parkinson’s disease substantially. Among people with sleep apnea who didn’t use CPAP treatment, rates of Parkinson’s diagnosis were nearly double compared to those who received therapy. This discovery reframes sleep apnea from a quality-of-life issue into a serious neurological risk factor.

The mechanism behind this connection involves oxygen deprivation. When throat muscles relax during sleep, breathing pauses repeatedly throughout the night. Blood pressure spikes, stress hormones flood the system, and crucially, the brain receives insufficient oxygen. Over months and years, this chronic oxygen deficit may stimulate the production of alpha-synuclein, a protein that becomes toxic at elevated levels. This toxic protein contributes directly to the degenerative process that defines Parkinson’s disease in the brain.

Why 80 Percent of Cases Go Undiagnosed

The tragedy of sleep apnea lies not in its rarity but in its invisibility. An estimated 80 to 90 percent of moderate-to-severe cases remain undiagnosed, transforming a treatable condition into a silent threat. People normalize symptoms—attributing loud snoring to aging, daytime fatigue to stress, frequent nighttime urination to getting older. Primary care physicians rarely screen for sleep apnea during routine checkups, leaving patients unaware they’re experiencing dozens of breathing interruptions nightly.

Surveys reveal that nearly 78 percent of adults cannot accurately define sleep apnea, and 57 percent misunderstand how CPAP therapy works. This knowledge gap delays diagnosis by years. Patients suffer needlessly through fatigue, cognitive decline, and cardiovascular stress while their risk of serious neurological disease quietly accumulates.

The Parkinson’s Connection: A Two-Way Street

The relationship between sleep apnea and Parkinson’s appears bidirectional. Not only does untreated apnea increase Parkinson’s risk, but approximately 40 percent of people already diagnosed with Parkinson’s disease also experience obstructive sleep apnea. This overlap creates a compounding crisis. Sleep fragmentation from apnea causes chronic fatigue and daytime sleepiness, both of which directly interfere with motor symptoms and medication effectiveness in Parkinson’s patients. The resulting exhaustion reduces independence in daily activities and accelerates cognitive decline.

Researchers theorize that loss of serotonin-producing nerve cells in the brain—a hallmark of Parkinson’s disease—may also impair the neural regulation of breathing during sleep, creating a neurological vulnerability to apnea. Understanding this connection opens new pathways for intervention and prevention.

Early Treatment Changes Everything

The encouraging news: timing matters enormously. A preliminary study presented at the American Academy of Neurology’s annual meeting found that people who started CPAP therapy within two years of a sleep apnea diagnosis showed significantly lower rates of subsequent Parkinson’s diagnosis. Specifically, early CPAP use reduced Parkinson’s cases by 2.3 per 1,000 people compared to untreated patients. This reduction suggests that restoring proper oxygenation and sleep quality during the critical early years following diagnosis may prevent or delay neurodegeneration.

CPAP machines work by delivering pressurized air through a mask, keeping airways open throughout the night. While adjustment takes time, consistent use restores restorative sleep cycles and maintains healthy oxygen levels in the brain. For anyone over 40 with risk factors—male gender, obesity, high blood pressure, or a family history of Parkinson’s—early screening and treatment represent powerful preventive medicine.

The Case for Immediate Action

The evidence converges on a single imperative: screening for sleep apnea should become routine, not exceptional. The cost of diagnosis—a simple overnight sleep study—pales against the cost of untreated disease: cardiovascular events, accidents from daytime drowsiness, cognitive decline, and now, substantially elevated neurological risk. For middle-aged and older adults, detecting and treating sleep apnea may rank among the most important preventive health decisions they make.